RxDoctor Payments Data

Margot Oneill, PA

Hematology & Oncology · Durham, NCNPI 1194809087

Payments from drug & device makers

$11,101in general payments, 2019–2025

Across 40 payments — averaging $277.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$9K
  • AbbVie$646
  • Daiichi Sankyo Inc.$279
  • Merck$264
  • Takeda Pharmaceuticals U.S.A., Inc.$170
  • Genentech USA, Inc.$113
  • plus $263 from 4 others

What the payments were for

  • Speaking & faculty fees$6,60059%
  • Travel & lodging$2,40122%
  • Food & beverage$2,07419%
  • Education$260%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,101 in reported general payments places this provider in the 50th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,461
Medicare patients
113
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase46$213,212
EliquisApixaban19$13,509
Sucralfate18$1,176
Oxycodone Hcl41$935
Pantoprazole Sodium77$710
Potassium Chloride17$645
Gabapentin27$519
Ondansetron Hcl29$487
Olanzapine13$325
Prochlorperazine Maleate16$314
Dexamethasone19$312
Omeprazole39$184
Triamcinolone Acetonide11$176
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$151
Morphine Sulfate11$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$646$213,21246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →